From Multiple Sclerosis Journal, July 30, 2015:
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis
Amal PR Samaraweera
Division of Clinical Neuroscience, Queen’s Medical Centre, University of Nottingham, UK
Stuart N Cohen
Nottingham University Hospitals NHS Trust, UK
Ela M Akay
Nottingham University Hospitals NHS Trust, UK
Nikos Evangelou
Division of Clinical Neuroscience, Queen’s Medical Centre, University of Nottingham, UK/Nottingham University Hospitals NHS Trust, UK
Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7 2UH, UK. nikos.evangelou@nottingham.ac.uk
Background:
Fingolimod was the first oral disease-modifying treatment for relapsing–remitting multiple sclerosis. It has previously been associated with the development of lymphoma.
Objective:
To describe a case of lymphomatoid papulosis, a CD30+ cutaneous lymphoproliferative disorder, in a patient taking fingolimod.
Methods:
Case study.
Results:
Our patient developed lymphomatoid papulosis 2 months after starting fingolimod. Histology confirmed the diagnosis. The drug was withdrawn. Resolution began only 2 days later.
Conclusions:
Lymphomatoid papulosis is a benign subtype of cutaneous T-cell lymphoma, but up to 20% of cases can transform to a malignant course. Patients on fingolimod and physicians caring for them should be mindful of the need to monitor the skin.
[Emphasis added.]
The abstract can be seen
here.